Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization277 mentions
- NVIDIAorganization265 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
Equillium, Inc.
organization2 mentionslast seen Oct 26, 2026
Biopharmaceutical company developing EQ504.
Relationships 4
Relationship
Equillium, Inc.developsEQ504
99% confidence2 supporting mentions
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGAROct 26, 2026Equillium, Inc. 8-K: Item 3.02: Unregistered Sales of Equity Securities; Item 7.01: Regulation FD Disclosure; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders
- filingSEC EDGAROct 5, 2026Equillium, Inc. 8-K: Item 8.01: Other Events
Equillium, Inc. (the Company) announced that the Company has received Human Research Ethics Committee approval and clearance from the Therapeutic Goods Administration in Australia under the Clinical Trial Notification scheme for its Phase 1 clinical trial of EQ504